What pathway do statins block?

Statins work by competitively blocking the active site of the first and key rate-limiting enzyme in the mevalonate pathway, HMG-CoA reductase. Inhibition of this site prevents substrate access, thereby blocking the conversion of HMG-CoA to mevalonic acid.

Do statins mimic mevalonate?

For reactions 2 and 1, inhibition of P. mevalonii HMG–CoA reductase by Lovastatin was competitive with respect to mevalonate or HMG–CoA and non-competitive with respect to NAD+ or NADH. This statin drug therefore mimics binding of the substrates but not of the coenzymes.

What does mevalonate pathway do?

The mevalonate pathway, fundamental for cholesterol synthesis, is one of the most important metabolic networks in the cell; it provides essential cell constituents, such as cholesterol, and some of its branches produce key metabolites, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate, necessary for …

Does mevalonate inhibit HMG-CoA reductase?

Regulation of HMG-CoA Reductase The second level of regulation is at the translation of the HMGR mRNA, which is inhibited by Farnesol, a derivative of the mevalonate pathway.

What happens when you inhibit HMG-CoA reductase?

Inhibition of HMG-CoA reductase, a rate-limiting enzyme in hepatic cholesterol synthesis by statins, results in the reduction of intracellular cholesterol content that in turn induces an increase in SREBP-2-mediated hepatic LDL receptor synthesis (Sahebkar and Watts, 2013b) (Chapter 11).

What is the meaning of HMG-CoA reductase inhibitors?

Listen to pronunciation. (HMG-koh-A ree-DUK-tays in-HIH-bih-ter) A substance that blocks an enzyme needed by the body to make cholesterol and lowers the amount of cholesterol in the blood. HMG-CoA reductase inhibitor drugs are called statins.

Are statins competitive inhibitors?

Abstract. Statins are competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis. Statins are widely and successfully used for lowering plasma cholesterol levels causing up to 45% reduction of plasma cholesterol and considerable reduction in risk of cardiovascular diseases.

What pathways is HMG-CoA involved?

β-Hydroxy β-methylglutaryl-CoA (HMG-CoA), also known as 3-hydroxy-3-methylglutaryl coenzyme A, is an intermediate in the mevalonate and ketogenesis pathways.

How statins bind to and inhibit their target HMG-CoA reductase?

Statins competitively inhibit the HMG-CoA reductase enzyme. Statins bind to the active site of the enzyme and change its structure. As the structure of the enzyme is changed, it cannot bind with the receptor, thus its activity is reduced.

What is the mechanism of action of HMG-CoA reductase inhibitor?

Mechanism of action: Drugs in this class are HMG-CoA reductase inhibitors. Recall from a previous discussion that the enzyme HMG-CoA reductase is an essential enzyme in the cholesterol synthesis pathway. By inhibiting this enzyme, HMG-CoA reductase inhibitors decrease cholesterol levels.

How do statins work HMG-CoA reductase?

Statins act by competitively binding to the catalytic domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase, HMGCR)8,9 and blocking the conversion of HMG-CoA to mevalonate, the rate-limiting step of cholesterol biosynthesis.

Why are statins competitive inhibitors?

Statins are effective competitive inhibitors as they bind HMG-CoA reductase approximately1000-fold more effectively than the natural substrate. The statin family of drugs block the conversion of HMG-CoA to mevalonate by inhibiting the rate-limiting enzyme of the mevalonate pathway, HMG-CoA reductase (a).

What do statins do to HMG-CoA?

How do statins work HMG?

How mevalonate is formed from acetyl-CoA during cholesterol synthesis?

Enzymatic reactions Acetoacetyl-CoA condenses with another Acetyl-CoA molecule to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA is reduced to mevalonate by NADPH. This is the rate limiting step in cholesterol synthesis, which is why this enzyme is a good target for pharmaceuticals (statins).

What is HMG pathway?

HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, official symbol HMGCR) is the rate-controlling enzyme (NADH-dependent, EC 1.1. 1.88; NADPH-dependent, EC 1.1. 1.34) of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids.

What are the effects of statins on Mevalonate synthesis?

However, the effects of statins extend beyond their cholesterol-lowering action, since inhibition of HMGR decreases the synthesis of all products downstream in the mevalonate pathway.

What is the role of mevalonate pathway in cholesterol production?

The mevalonate pathway is not only responsible for the production of cholesterol but also isoprenoid lipids such as IPP (five carbon), FPP (15 carbon), and GGPP (20 carbon), the latter two being substrates for protein isoprenylation (see Fig. 5 ).

Is the mevalonate pathway sensitive to statin-induced apoptosis in multiple myeloma?

We show that dysregulation of the mevalonate pathway is a key determinant of sensitivity to statin-induced apoptosis in multiple myeloma. In sensitive cells, the classic feedback response to statin exposure is lost.

What are the steps in the mevalonate pathway?

The first step condenses two acetyl-CoA molecules to yield acetoacetyl-CoA. This is followed by a second condensation to form HMG-CoA (3-hydroxy-3- methyl-glutaryl-CoA). Reduction of HMG-CoA yields (R)-mevalonate. These first 3 enzymatic steps are called the upper mevalonate pathway.